3 min read
Part One: Biologics and the Problem with Residual DNA
Part One: Biologics and the Problem with Residual DNA
The biologics market represents the leading edge of novel therapeutics and is the fastest-growing cross-section of the pharmaceutical industry—by some accounts, increasing as much as eight percent annually, or twice the growth rate of small molecule therapeutics. With advancements in DNA technology and increasing investments in personalized medicine, the sky is the limit for the biologics industry.
In Summary
The Alcami laboratory network and suite of biologics services support every stage of drug development, from early phase clinical trials through drug approval and commercialization. For decades, our clients have relied on our expertise, technology, track record, and regulatory infrastructure to advance the launch of their novel biological products.
[1] Consistent yield can be accomplished, but is a challenge from a development perspective, especially relative to small molecules.
3 min read
Part One: Biologics and the Problem with Residual DNA
4 min read
Recently, contract development and manufacturing organizations (CDMOs) involved in the pharmaceutical industry have seen massive growth as demand for...
2 min read
Part Two: Cell-Based Bioassays